Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 62,970 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 62,970 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $0.45, for a total value of $28,336.50. Following the completion of the transaction, the director owned 1,041,342 shares in the company, valued at approximately $468,603.90. The trade was a 5.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total value of $36,934.85.
• On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.50, for a total value of $11,092.00.
• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $22,745.16.
• On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.70, for a total value of $214,018.70.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total value of $9,659.10.
• On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $4,733.40.
• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total value of $34,533.36.
• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $42,627.62.

Werewolf Therapeutics Price Performance

Shares of HOWL stock traded up $0.01 during trading hours on Wednesday, reaching $0.44. The company had a trading volume of 1,033,082 shares, compared to its average volume of 460,756. Werewolf Therapeutics, Inc. has a 12 month low of $0.40 and a 12 month high of $2.38. The business has a fifty day simple moving average of $0.80 and a 200-day simple moving average of $0.79. The company has a market cap of $21.29 million, a price-to-earnings ratio of -0.35 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. On average, equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOWL has been the topic of a number of recent analyst reports. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.75.

Institutional Trading of Werewolf Therapeutics

A number of large investors have recently bought and sold shares of the company. Susquehanna International Group LLP increased its position in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after buying an additional 13,439 shares during the last quarter. Vontobel Holding Ltd. boosted its holdings in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares during the period. Regal Investment Advisors LLC boosted its holdings in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares during the period. Bank of America Corp DE boosted its holdings in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares during the period. Finally, Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $48,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.